Afatinib reimbursement policy 2025: medical insurance indications and reimbursement ratio

Afatinib has been included in China's National Reimbursement List and has become a targeted treatment drug for lung cancer routinely used in hospitals in many places. As a second-generation EGFR-TKI targeted drug, afatinib is mainly used to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR-sensitive mutations (such as Del19, L858R), and also for patients with locally advanced or metastatic squamous NSCLC during or after receiving platinum-based chemotherapy.

From the perspective of medical insurance policies, afatinib is currently classified as a Class B medical insurance drug, and the reimbursement ratio is usually between 60% and 80%. The specific ratio varies according to regional policies, hospital levels, and insurance types. Some cities have additional subsidy policies for patients with major diseases or malignant tumors, further reducing patients’ actual out-of-pocket expenditures. It should be noted that the prerequisite for medical insurance reimbursement must meet the indication standards for afatinib, that is, the patient is confirmed to have an EGFR sensitive mutation through genetic testing, and the treatment plan is prescribed by a specialist.

In addition, when making medical insurance settlement, patients must purchase drugs through designated medical institutions or pharmacies, and bring their medical insurance cards and relevant diagnostic data. Some areas also require registration of electronic prescriptions or inclusion in multidisciplinary (MDT) discussions before prescribing drugs. Therefore, patients are advised to confirm the specific procedures with the medical insurance department of their hospital in advance.

It is worth mentioning that some local governments have also set up special medical assistance policies or "targeted drug assistance plans" for patients with financial difficulties. Some afatinib suppliers also provide patient assistance programs (PAP) to provide preferential channels for patients who are not eligible for full reimbursement by medical insurance.

In summary, afatinib will be widely covered by medical insurance in 2025, with clear indications and a high reimbursement rate. Patients should complete EGFR mutation testing through a regular hospital before treatment and confirm the medical insurance policy details to minimize the financial burden.

Reference materials:https://www.giotrif.com/